ClinVar Miner

Submissions for variant NM_007294.3(BRCA1):c.1244T>C (p.Val415Ala) (rs1064796031)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 1
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
GeneDx RCV000480438 SCV000572403 uncertain significance not provided 2016-12-01 criteria provided, single submitter clinical testing This variant is denoted BRCA1 c.1244T>C at the cDNA level, p.Val415Ala (V415A) at the protein level, and results in the change of a Valine to an Alanine (GTT>GCT). Using alternate nomenclature, this variant would be defined as BRCA1 1363T>C. This variant has been reported in French families with breast/ovarian cancer (Anczukow 2008). BRCA1 Val415Ala was not observed in approximately 6,500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, suggesting it is not a common benign variant in these populations. Since Valine and Alanine share similar properties, this is considered a conservative amino acid substitution. BRCA1 Val415Ala occurs at a position that is not conserved and is located in a region known to interact with multiple proteins (Paul 2014). In silico analyses are inconsistent regarding the effect this variant may have on protein structure and function. Based on currently available evidence, it is unclear whether BRCA1 Val415Ala is a pathogenic or benign variant. We consider it to be a variant of uncertain significance.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.